Immunology Market by Type, Distribution Channel, and Geography - Forecast and Analysis 2023-2027
| Published: Oct 2023 | Pages: 164 | SKU: IRTNTR71364 |
Immunology Market Forecast 2023-2027
The immunology market size is estimated to grow by USD 56.07 billion at a CAGR of 8.84% between 2022 and 2027. The growth of the market depends on several factors, including the growing organ transplantation, the growing cases of infectious diseases, and the hurdles in the approval of biosimilars.
It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
What will be the Size of the Immunology Market During the Forecast Period?
To learn more about this report, View Report Sample
Market Dynamics
The hurdles in the approval of biosimilars are notably driving the market growth, although factors such as the lack of awareness may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Driver
Hurdles in the approval of biosimilars are the key factor driving the growth of the global market. A biosimilar can be defined as an approved biological product based on demonstrating a high degree of similarity to an already approved product of biological origin. Additionally, biosimilars do not show clinically significant deviations in safety profile or efficacy compared to reference products. Biosimilars allow for minor differences in clinically inactive ingredients. Additionally, they are a more affordable treatment option for patients as they are approved by the U.S. Food and Drug Administration via various shortcuts and avoid costly duplication of clinical trials. Lower development costs lower the price of biosimilars compared to patented products.
The clearance of biosimilars from the US FDA is slow, as obtaining guidance documents for a biosimilar is time-consuming. For instance, INFLECTRA was cleared by the US FDA after two months of House Subcommittee hearings. As per the Biologics Price Competition and Innovation (BPCI) Act, it is not essential for the US FDA to issue guidance before approving a biosimilar application, but this guide will help to ensure successful implementation. As biosimilar approvals get delayed, the substitutes will not enter the global market. This makes the global market continue to grow during the forecast period.
Significant Trends
A significant pipeline of immunology is the primary trend in the global market growth. There are multiple promising immunological agents in the pipeline, which will boost market growth after their approval. Approval of a new treatment increases treatment options and increases demand for that treatment regimen. Around 51 molecules are in various stages of clinical trials worldwide. Of these, 22 molecules are in Phase II, four are in Phase III, 16 are in Phase I, and the rest are in Phase I/II clinical trials.
One of the most promising molecules from AbbVie Inc. risankizumab (SKYRIZI) is under development. Boehringer Ingelheim and AbbVie Inc. jointly worked on the molecule to get approval for new indications such as psoriasis, psoriatic arthritis, and Crohn's disease. Another molecule from AbbVie ABBV-157 is under Phase I as of October 2021 for the treatment of psoriatic arthritis. Thus, these developments will lead to the global market growth during the forecast period.
Major Challenge
Lack of awareness of immunology is a major challenge to the growth of the global market. Lack of awareness of immune-mediated malignancies will adversely affect the growth of the global market as it limits the use of drugs. Awareness issues make it difficult to achieve true marketability of available products. Allergies are one of the growing health problems that affect people's daily lives. Despite its high prevalence, allergies are still underdiagnosed and undertreated due to a lack of information.
Also, there is a significant lack of awareness among people about fatigue as a serious symptom of rheumatoid arthritis. The NIH also states that more than one-third of patients experiencing rhinitis and asthma symptoms remain undiagnosed and have decreased their quality of life. Although effective treatments are available, factors such as individual attitudes, beliefs, and inadequate communication between clinician and patient contribute to poor treatment adherence, especially in chronic diseases such as allergies and asthma. Thus, the lack of awareness is a major challenge and is likely to hinder the global market during the forecast period.
Key Market Customer Landscape
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Who are the Major Immunology Market Players?
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Astellas Pharma Inc: The company offers V Cells therapy which is designed to enhance the immune system for killing cancer cells. Also, the company is involved in offering a wide range of products such as XTANDI, XOSPATA, Evrenzo used for the treatment of chronic diseases related to cancer and kidney treatment.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
- 3SBio Inc.
- AbbVie Inc.
- Amgen Inc.
- Antares Pharma Inc.
- Biogen Inc.
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Horizon Therapeutics Plc
- ImmuNext Inc.
- Incyte Corp.
- Johnson and Johnson Services Inc.
- Merck KGaA
- Mitsubishi Chemical Group Corp.
- Novartis AG
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
What is the Fastest-Growing Segment in the Market?
The market share growth by the immunosuppressants segment will be significant during the forecast period. Immunosuppressants are also known as anti-rejection drugs. This class of drugs either suppresses or reduces the response of the body's immune system.
Get a glance at the market contribution of various segments View the PDF Sample
The immunosuppressants segment was valued at USD 44.75 billion in 2017 and continued to grow until 2021. These drugs have large applications in organ transplantation where the chances of organ rejection are high, as the body's immune system identifies the new organ as a foreign agent and tends to attack it, resulting in rejection. This is because the immune system perceives transplanted organs as foreign items and mounts an immunological response against them, causing the organs to be destroyed while also affecting other body components. Immunosuppressants prevent a patient body from having a hyper-immune response. Such factors will increase segment growth during the forecast period.
Which are the Key Regions for the Market?
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In North America, it is expected to register moderate growth during the forecast period owing to the increased funding from government and non-government bodies along with the rise in the prevalence rate of chronic diseases such as rheumatoid arthritis and cancer. According to the CDC, in January 2021, the incidence rate of female breast cancer was 123.9 per 100,000 people in the US. The evidence from the drug trials revealed that the effect of anti-cancer drugs lasts longer when immuno-booster drugs are given along with the anti-cancer drugs. The use of products in cancer therapy supports the market growth during the forecast period.
Segment Overview
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
- Type Outlook (USD Billion, 2017 - 2027)
- Immunosuppressants
- Immuno boosters
- Distribution Channel Outlook (USD Billion, 2017 - 2027)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Region Outlook (USD Billion, 2017 - 2027)
- North America
- The U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- ROW
- Australia
- Argentina
- Rest of the world
- North America
Market Analyst Overview
The Market addresses a range of infections and immunological disorders, including autoimmune diseases like type 1 diabetes, ankylosing spondylitis, and inflammatory bowel disease. Research published in the Annals of the Rheumatic Diseases often influences treatment approaches and patents for new therapies.
Key medications like Leflunomide and Monoclonal Antibodies (mAbs), including fusion proteins, are crucial for managing autoimmune disorders, but treatment costs and adverse effects remain concerns. These therapies are essential for prophylaxis of organ rejection post-transplant. The market is driven by an increasing understanding of environmental factors influencing autoimmune diseases and the development of novel therapies. Companies like Lupin play a significant role in developing treatments, focusing on improving disease indication specificity and reducing side effects.
|
Immunology Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
164 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 8.84% |
|
Market growth 2023-2027 |
USD 56.07 billion |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
8.37 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 41% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
3SBio Inc., AbbVie Inc., Amgen Inc., Antares Pharma Inc., Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Horizon Therapeutics Plc, ImmuNext Inc., Incyte Corp., Johnson and Johnson Services Inc., Merck KGaA, Mitsubishi Chemical Group Corp., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., UCB SA, and GlaxoSmithKline Plc |
|
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
- Precise estimation of the size of the market size and its contribution to the parent market
- Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
- Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
- Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global immunology market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on global immunology market 2017 - 2021 ($ billion)
- 4.2 Type Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ billion)
- 4.3 Distribution Channel Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ billion)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Type
- 6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
- 6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type
- 6.3 Immunosuppressants - Market size and forecast 2022-2027
- Exhibit 34: Chart on Immunosuppressants - Market size and forecast 2022-2027 ($ billion)
- Exhibit 35: Data Table on Immunosuppressants - Market size and forecast 2022-2027 ($ billion)
- Exhibit 36: Chart on Immunosuppressants - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Immunosuppressants - Year-over-year growth 2022-2027 (%)
- 6.4 Immuno boosters - Market size and forecast 2022-2027
- Exhibit 38: Chart on Immuno boosters - Market size and forecast 2022-2027 ($ billion)
- Exhibit 39: Data Table on Immuno boosters - Market size and forecast 2022-2027 ($ billion)
- Exhibit 40: Chart on Immuno boosters - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Immuno boosters - Year-over-year growth 2022-2027 (%)
- 6.5 Market opportunity by Type
- Exhibit 42: Market opportunity by Type ($ billion)
- Exhibit 43: Data Table on Market opportunity by Type ($ billion)
7 Market Segmentation by Distribution Channel
- 7.1 Market segments
- Exhibit 44: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 45: Data Table on Distribution Channel - Market share 2022-2027 (%)
- 7.2 Comparison by Distribution Channel
- Exhibit 46: Chart on Comparison by Distribution Channel
- Exhibit 47: Data Table on Comparison by Distribution Channel
- 7.3 Hospital pharmacies - Market size and forecast 2022-2027
- Exhibit 48: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 49: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 50: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 51: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
- 7.4 Retail pharmacies - Market size and forecast 2022-2027
- Exhibit 52: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 53: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 54: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
- 7.5 Online pharmacies - Market size and forecast 2022-2027
- Exhibit 56: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
- 7.6 Market opportunity by Distribution Channel
- Exhibit 60: Market opportunity by Distribution Channel ($ billion)
- Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ billion)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2022-2027 (%)
- Exhibit 64: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Europe - Market size and forecast 2022-2027
- Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.5 Asia - Market size and forecast 2022-2027
- Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 Germany - Market size and forecast 2022-2027
- Exhibit 87: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 88: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 89: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.9 UK - Market size and forecast 2022-2027
- Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)
- 9.10 China - Market size and forecast 2022-2027
- Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.11 Japan - Market size and forecast 2022-2027
- Exhibit 99: Chart on Japan - Market size and forecast 2022-2027 ($ billion)
- Exhibit 100: Data Table on Japan - Market size and forecast 2022-2027 ($ billion)
- Exhibit 101: Chart on Japan - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on Japan - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ billion)
- Exhibit 104: Data Tables on Market opportunity by geography ($ billion)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 108: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 109: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification
- 12.3 AbbVie Inc.
- Exhibit 111: AbbVie Inc. - Overview
- Exhibit 112: AbbVie Inc. - Product / Service
- Exhibit 113: AbbVie Inc. - Key news
- Exhibit 114: AbbVie Inc. - Key offerings
- 12.4 Amgen Inc.
- Exhibit 115: Amgen Inc. - Overview
- Exhibit 116: Amgen Inc. - Product / Service
- Exhibit 117: Amgen Inc. - Key offerings
- 12.5 Astellas Pharma Inc.
- Exhibit 118: Astellas Pharma Inc. - Overview
- Exhibit 119: Astellas Pharma Inc. - Product / Service
- Exhibit 120: Astellas Pharma Inc. - Key news
- Exhibit 121: Astellas Pharma Inc. - Key offerings
- 12.6 Bristol Myers Squibb Co.
- Exhibit 122: Bristol Myers Squibb Co. - Overview
- Exhibit 123: Bristol Myers Squibb Co. - Product / Service
- Exhibit 124: Bristol Myers Squibb Co. - Key news
- Exhibit 125: Bristol Myers Squibb Co. - Key offerings
- 12.7 Eli Lilly and Co.
- Exhibit 126: Eli Lilly and Co. - Overview
- Exhibit 127: Eli Lilly and Co. - Product / Service
- Exhibit 128: Eli Lilly and Co. - Key news
- Exhibit 129: Eli Lilly and Co. - Key offerings
- 12.8 F. Hoffmann La Roche Ltd.
- Exhibit 130: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 131: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 132: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 133: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 134: F. Hoffmann La Roche Ltd. - Segment focus
- 12.9 GlaxoSmithKline Plc
- Exhibit 135: GlaxoSmithKline Plc - Overview
- Exhibit 136: GlaxoSmithKline Plc - Business segments
- Exhibit 137: GlaxoSmithKline Plc - Key news
- Exhibit 138: GlaxoSmithKline Plc - Key offerings
- Exhibit 139: GlaxoSmithKline Plc - Segment focus
- 12.10 Incyte Corp.
- Exhibit 140: Incyte Corp. - Overview
- Exhibit 141: Incyte Corp. - Product / Service
- Exhibit 142: Incyte Corp. - Key offerings
- 12.11 Johnson and Johnson Services Inc.
- Exhibit 143: Johnson and Johnson Services Inc. - Overview
- Exhibit 144: Johnson and Johnson Services Inc. - Business segments
- Exhibit 145: Johnson and Johnson Services Inc. - Key news
- Exhibit 146: Johnson and Johnson Services Inc. - Key offerings
- Exhibit 147: Johnson and Johnson Services Inc. - Segment focus
- 12.12 Merck KGaA
- Exhibit 148: Merck KGaA - Overview
- Exhibit 149: Merck KGaA - Business segments
- Exhibit 150: Merck KGaA - Key news
- Exhibit 151: Merck KGaA - Key offerings
- Exhibit 152: Merck KGaA - Segment focus
- 12.13 Mitsubishi Chemical Group Corp.
- Exhibit 153: Mitsubishi Chemical Group Corp. - Overview
- Exhibit 154: Mitsubishi Chemical Group Corp. - Business segments
- Exhibit 155: Mitsubishi Chemical Group Corp. - Key offerings
- Exhibit 156: Mitsubishi Chemical Group Corp. - Segment focus
- 12.14 Novartis AG
- Exhibit 157: Novartis AG - Overview
- Exhibit 158: Novartis AG - Business segments
- Exhibit 159: Novartis AG - Key offerings
- Exhibit 160: Novartis AG - Segment focus
- 12.15 Pfizer Inc.
- Exhibit 161: Pfizer Inc. - Overview
- Exhibit 162: Pfizer Inc. - Product / Service
- Exhibit 163: Pfizer Inc. - Key news
- Exhibit 164: Pfizer Inc. - Key offerings
- 12.16 Takeda Pharmaceutical Co. Ltd.
- Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key offerings
- 12.17 UCB SA
- Exhibit 169: UCB SA - Overview
- Exhibit 170: UCB SA - Product / Service
- Exhibit 171: UCB SA - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 172: Inclusions checklist
- Exhibit 173: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 174: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 175: Research methodology
- Exhibit 176: Validation techniques employed for market sizing
- Exhibit 177: Information sources
- 13.5 List of abbreviations
- Exhibit 178: List of abbreviations
- growth due to the increasing number of tests for infectious and chronic diseases: The incidence of infectious and chronic diseases has increased over the past decade. The outbreak of the COVID-19 pandemic in 2020 has increased the demand for laboratory testing for COVID-19 across the world. An increase in demand for laboratory testing for infectious diseases, such as COVID-19 and chronic diseases, will be a driver for the life sciences tools and services industry in the future. The growth of the tools and services industry will continue to be strong in emerging markets such as China and India. Developed economies such as Japan and the EU will exhibit moderate growth rates.
- product development to decrease prices: As the pricing pressure increases, life sciences tools manufacturers will have to rethink product development processes. A value first product design philosophy can help control costs and deliver what customers value the most.
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
immunology market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis